Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B
Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B
Shots:
- Esperion to receive $150M upfront, $150M sales milestones and up to $900M regulatory
milestones including royalties. Daiichi to get exclusive commercialization rights for Esperion’s bempedoic acid and bempedoic acid /ezetimibe drug in EU and Switzerland - Esperion plans for the file NDA and MAA for bempedoic acid / ezetimibe to the US FDA and
EMA in Q1’19 & Q2’19 respectively, with its expected results in H1’19 - Bempedoic Acid is a once daily ATP Citrate Lyase inhibitor, indicated for the reduction of LDL-C by activating LDL receptor
Click here to read full press release/ article | Ref: Esperion | Image: Investors